And in June, Bristol Myers Squibb launched Zeposia, its newly approved oral medication for relapsing forms of multiple sclerosis.In the quarter prior to the health crisis, revenue climbed 7.1%, with the nutrition, diagnostics, established pharmaceuticals, and medical devices segments all posting growth.